You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

19 Items
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Pemetrexed - Combination with Platinum for Non-Small Cell Lung Cancer
Drugs Used:
pembrolizumab (Compassionate),
Jul 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Aug 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Pemetrexed - Combination with Platinum for Non-Small Cell Lung Cancer
Drugs Used:
pembrolizumab (Compassionate),
Aug 2019
Cancer Type: Gynecologic, Ovary     
Intent: Palliative
Funding:
New Drug Funding Program
    Pegylated liposomal doxorubicin with carboplatin - platinum-sensitive recurrent ovarian, fallopian tube and primary peritoneal cancer
May 2019
Cancer Type: Genitourinary, Prostate     
Intent: Palliative
Funding:
ODB - General Benefit
  • flutamide
Oct 2016
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Curative, Palliative
Nov 2017
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    cyclophosphamide - oral tablets
Updated
Sep 2019
Cancer Type: Skin, Melanoma     
Intent: Adjuvant
Drugs Used:
pembrolizumab (Compassionate)
Jul 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and No Prior Ipilimumab
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and Prior Ipilimumab
Updated
Sep 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer (Second or Subsequent Line)
New Drug Funding Program
    Pembrolizumab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Updated
Sep 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Drugs Used:
pembrolizumab (Compassionate)
Updated
Sep 2019
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Palliative
Drugs Used:
pembrolizumab (Compassionate)
Updated
Sep 2019